Addressing Orthostatic Hypotension in Heart Failure: Pathophysiology, Clinical Implications and Perspectives

• Published in: Journal of cardiovascular translational research 2020-08, Vol.13 (4), p.549-569
• Main Authors: Soloveva, Anzhela, Fedorova, Darya, Villevalde, Svetlana, Zvartau, Nadezhda, Mareev, Yury, Sitnikova, Mariya, Shlyakhto, Evgeny, Fudim, Marat
• Format: Article
• Language: English
• Subjects: Biomedical Engineering and Bioengineering; Biomedicine; Cardiology; Human Genetics; Medicine; Medicine & Public Health; Review; Special Issue: Volume Management in Heart Failure
• ISSN: 1937-5387; 1937-5395
• DOI: 10.1007/s12265-020-10044-1

Heart failure (HF)is a condition at high risk for orthostatic hypotension (OH)given the large proportion of patients at an advanced age and high burden of comorbidities contributing to OH, as well as a high prevalence of medications with neurovascular and volume modulating properties. Early identification of OH in HF seems to be crucial as OH can have an impact on patient symptoms, activity level and independence, be a marker of specific pathophysiological changes or be an indicator of need for personalized treatment. OH might contribute significantly to bad enough prognosis in HF, as, besides a risk of falls and cognitive decline, it was found to be associated with cardiovascular morbidity and mortality. In this review, we aimed to incentivize the routine use of orthostatic testing in HF, as well as stimulate future research in this field, which could lead to significant advances in the treatment and outcomes.